X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GEN-001 is being developed as an orally administered microbiome therapeutic with Lactococcus lactis, a single strain bacteria isolated from a healthy human. Its anticancer efficacy was proven by activating immune activity of cancer cells.
Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology Product Name: GEN-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2023
Details:
Upon the execution of the agreement, Genome will conduct a phase 2 clinical trial to evaluate the safety and efficacy of its immuno-oncology microbiome therapeutic, GEN-001, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, in patients with biliary tract cancer.
Lead Product(s): GEN-001,Pembrolizumab
Therapeutic Area: Oncology Product Name: GEN-001
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 03, 2022
Details:
The collaboration follows in just a year after signing the first agreement with Merck KGaA, Darmstadt, Germany and Pfizer in December 2019 to conduct the first combination clinical trial of avelumab (BAVENCIO®) and GEN-001.
Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology Product Name: GEN-001
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 09, 2021
Details:
The phase 1 study aims to determine the RP2D (recommended Phase 2 dose) of GEN-001 in combination with BAVENCIO® (avelumab).
Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology Product Name: GEN-001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
Funding will be used to support ongoing clinical development of Scioto’s lead product, SB-121, as a microbiome treatment for diseases affecting the gut-brain axis and gut injury.
Lead Product(s): SB-121
Therapeutic Area: Gastroenterology Product Name: SB-121
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Scioto Biosciences
Deal Size: $26.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 11, 2020
Details:
Genome & Company which sponsor clinical trial of combination therapy of anti-cancer microbiome and anti-PD1/anti-PD-L1 drug receives FDA IND clearance for GEN-001,
Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Details:
Clinical partnership of phase 1/1b combination clinical trial with Genome & Company's GEN-001, and avelumab, Merck KGaA, Darmstadt, Germany and Pfizer Inc.'s anti-PD-L1 antibody in cancer.
Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
